Medical Marijuana, Inc. Announces Investment in AXIM Biotechnologies
Cutting-Edge Global Industrial Hemp-Based Biotechnology Company Brings Added Diversity in Food and Pharmaceuticals to MJNA’s Growing Investment Portfolio
SAN DIEGO, June 30, 2015 /Weed Wire/ — Medical Marijuana, Inc. (OTC Pink:MJNA) would like to inform the public and shareholders that it holds 14,943,650 shares of common stock and 500,000 shares of preferred stock in AXIM Biotechnologies(AXIM), a cutting-edge biotechnology innovator.
Stuart W. Titus, PhD, President and CEO of Medical Marijuana Inc. mentions: “We are extremely excited to announce our strategic ownership interest in AXIM Biotech and explain to MJNA’s shareholders some of the important innovations that Dr. Anastassov and the AXIM team are focused on. AXIM Biotech’s recent announcements include hemp-based innovations that provide consumers a wide variety of new options worldwide.”
AXIM Biotech is a unique biotechnology company focused on global research, development and production of pharmaceutical, food, nutraceutical and cosmetic products as well as biofuels derived from cannabinoids. AXIM Biotech is focusing its efforts on unique proprietary mechanisms for the delivery of cannabinoids (e.g. CBD, CBG, etc.).
George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech states, “AXIM is a unique hemp-derived biosciences corporation where the responsibility for environmental protection and conservation meets the passion for development of innovative biotechnological applications for problems for which there are currently no solutions. The cannabis plant provides ample opportunity for innovative, sometimes revolutionary products. AXIM has realized the vast potential in oral health products based on cannabinoids, in particular CBG, and has filed intellectual property applications to protect its numerous IP.”
AXIM Biotech recently announced that it is the exclusive license recipient to the world’s first controlled-release cannabinoid chewing gum. This opens two markets for product development and distribution: food with CanChew Plus(R) and pharmaceutical with MedChew RX(TM), which is undergoing clinical trials in preparation for registration with FDA and EMA. The Company also recently unveiled the world’s first oral care and cosmetic lines, ORAXIMAX(TM) and RENECANN(TM), containing cannabigerol (CBG).
The global pharmaceutical market is reported to be potentially worth nearly $1.6 trillion by 2020. AXIM Biotech intends to develop innovative pharmaceutical delivery systems and API (active pharmaceutical ingredients) for treatment of conditions such as Parkinson’s disease, Alzheimer’s disease, ADHD (attention deficit hyperactivity disorder), PTSD, autism, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBS, IBD, Crohn’s disease and more. All of these efforts are based on proprietary IP.
Additional markets where AXIM Biotech intends to play a significant role are:
- Nutraceutical – Global Potential $207 Billion by 2016
- Phytoplant/Botanicals – Global Current Market $83 Billion
- R&D – Drug Discovery a Global $25 Billion Market
- Alternative Energy – Global Biofuels $185.3 Billion by 2021
- Manufacturing – 16% of Global GDP and Growing
Leading AXIM Biotechnologies is an international executive team of highly skilled and specialized professionals. Its members are responsible for the Company’s strategic initiatives and global operations. Through various committees, they oversee operations and business performance, strategy and planning, future and current product manufacturing, risk management, research and development, external affairs, and internal governance.
Dr. George E. Anastassov, MD, DDS, MBA – Chief Executive Officer
Dr. Philip A. Van Damme, DMD, MD, PhD – Chief Medical Officer
Lekhram Changoer, MSc. BSc. – Chief Technology Officer
AXIM Biotechnologies‘ industry-leading advisory board is composed of world leaders in their respective fields. AXIM’s Board of Advisors provides the Company with extensive expertise.
Members of the AXIM Board of Advisors include: Professor Renger Witkamp, Professor John Zajicek, Prof. Jacques Meis, Dr. Arno Hazekamp, Warren Hutchins, and Dr. Murad A. Sunalp.
AXIM Biotech has been featured by media outlets including: FOX Business, MainStreet.com, MJ Freeway, Chemical & Engineering News, Dental Tribune, Pharmaceutical Commerce, Dental Products Report and MJINews.
To learn more about the Company, visit AXIM Biotech’s website.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 858-380-5478.
About Medical Marijuana, Inc.
Our mission is to be the premier hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com.
About AXIM Biotechnologies
AXIM Biotechnologies (AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell and distribute hemp-based products and are involved with the federally legal distribution of hemp-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT: For further information, please contact:
Public Relations contact:
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
GH Investment Advisors
550 West “C” Street, Ste. 2040
San Diego, CA 92101
Office: (858) 264-6500
Toll Free: (877) 964-6463
The post Medical Marijuana, Inc. Announces Investment in AXIM Biotechnologies appeared first on MJI News.